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Introduction
C2B8 is a chimeric mouse/human monoclonal antibody (mAb) directed against the human B cell-restricted cell surface antigen CD20. [1] [2] [3] This antibody is used as an alternative medication of non-Hodgkin lymphomas of the B cell type (B-NHL) in clinical trials, where it promotes a rapid and efficient depletion of normal and neoplastic B cells with a response rate of about 50% and progression-free intervals of the disease for up to 12 months. [4] [5] [6] [7] [8] The reason for the efficient elimination of B cells induced by mAb C2B8 in vivo is still incompletely understood. Results from in vitro studies demonstrate that binding of mAb C2B8 to CD20 cell surface molecules on B cells induces complementdependent lysis of target cells as well as antibody-dependent cellular cytotoxicity mediated by macrophages and NK cells. 1, [9] [10] [11] [12] Yet it is more and more believed that signalling mechanisms induced by mAb C2B8 leading to apoptosis are potentially more important, since crosslinking of surface CD20 molecules with mAb C2B8 induces growth arrest and apoptosis in B cells. [13] [14] [15] [16] [17] [18] [19] Correspondence Recent studies have clearly shown that dendritic cells (DC) can ingest apoptotic or necrotic cells and present peptides thereof on MHC class II but also on MHC class I molecules. [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] The immunological consequences of such a cross-presentation event are currently hotly debated. 29, 30 Whereas necrotic cell material is preferentially considered as being immunogenic, apoptosis is generally thought of as being an immunologically innocuous or even tolerizing event. However, there are exceptions to this rule such as apoptotic death after certain viral or bacterial infections. 34, 35 The reason for this heterogeneity seems to be whether a particular dying cell contains signals that stimulate DC maturation or not, since only mature DC are efficient stimulators of T cell responses. 36 The potentially important immuno-stimulatory properties of B cell-derived debris caused by engagement of CD20 with mAb C2B8 have not been analyzed so far. This prompted us to investigate in this study whether mAb C2B8-treated, apoptotic target cells upon ingestion and processing by DC might induce potentially protective CD8 + cytotoxic T cell (CTL) responses against target cell-associated antigens or whether such a cross-presentation situation might primarily anergize effector cells. In order to address this question, we selected CD20 + Daudi Burkitt lymphoma as a model system. Daudi cells strongly express CD20 and are sensitive to C2B8 treatment. 13 Moreover, Daudi cells do not express intact MHC class I molecules on their surface and are therefore unable to directly stimulate CD8 + T cell responses. 37, 38 Priming of CTL against Daudi-derived antigens would thus depend on the delivery of peptides to MHC class I + antigen-presenting cells. The results presented in this study demonstrate that C2B8 treatment of CD20 + lymphoma cells promotes uptake and cross-presentation of lymphoma cell-derived peptides on cocultured DC, which finally allows an efficient activation of specific CTL. Thus, treatment of tumor cells with mAb C2B8 might not only initiate their killing and elimination but may also induce cytotoxic T cell responses against tumor cellderived peptides.
Materials and methods

Media, reagents and chemicals
The cell culture medium RPMI 1640 (Gibco, Paisley, UK) was supplemented with 2 mm l-glutamine, 100 U/ml penicillin, 100 g/ml streptomycin and 10% of heat inactivated, fetal calf serum (FCS). The endotoxin concentration of the medium was less than 10 pg/ml. Recombinant human GM-CSF, IL-4 and IL-2 were kindly provided by Novartis Research Institute (Vienna, Austria). IL-7 and IL-12 were purchased from R&D Systems (Minneapolis, MN, USA). Annexin-V FITC was obtained from Caltag (Burlingame, CA, USA). Propidium iodide (PI), sodium citrate, Triton X-100 and LPS from Escherichia Leukemia coli (serotype 0127-B8) were purchased from Sigma Chemie (Deisenhofen, Germany).
Antibodies
The following murine monoclonal antibodies (mAbs) were generated in our laboratory: VIAP (calf intestine alkaline phosphatase specific): VIT4 (CD4), VIT8 (CD8), VIM12 (CD11b), VIM13 (CD14), 4D3 (CD33), VIC-Y1 (CD74), 1/47 (MHC class II), VIG-C2 (anti-human IgG) and mAb LA-45 against free ␣-chains of MHC class I. Hybridomas producing the MHC class I mAb W6/32 and CD40 mAb G28-5 were obtained from American Tissue Culture Connection (ATCC; Rockville, MD, USA). The CD3 mAb UCHT-1 and the CD14 mAb MEM18 were kindly provided by An der Grub (Bio Forschungs, Kaumberg, Austria) and the CD19 mAb HD37 was a gift of G Moldenhauer (Division of Molecular Immunology, German Cancer Research Center, Heidelberg, Germany). The CD83 mAb HB-15 and the CD16 mAb 3G8 were purchased from Caltag and the CD86 mAb IT2.2 from PharMingen (San Diego, CA, USA). The chimeric mAb C2B8 against CD20 was kindly provided by Roche Austria (Vienna, Austria). Purified human IgG (Beriglobin P*) was obtained from Centeon Pharma (Marburg, Germany) and was used as negative control reagent.
Cell lines
The Burkitt lymphoma cell line Daudi (HLA-A1,10; B17,16; Cw3,w6)32 was obtained from ATCC. The EBV-transformed lymphoblastoid B cell lines (LCL) OM-LCL (HLA-A1,31; B7,49; Cw7) was generated in our laboratory and LCL-5170 (HLA-A34; B14; Cw8) was a kind gift of G Fischer from the Department of Blood Group Serology (University of Vienna, Vienna, Austria).
Cell preparation
PBMCs were isolated from heparinized whole blood of healthy donors by standard density gradient centrifugation with Ficoll-Paque (Pharmacia, Uppsala, Sweden). Subsequently, monocytes and T cells were separated by magnetic sorting using the MACS technique (Miltenyi Biotech, Bergisch Gladbach, Germany) as described previously. 33 Monocytes were enriched by using the biotinylated CD14 mAb VIM 13 (purity Ͼ95%). Purified T cells were obtained through negative depletion of CD11b, CD14, CD16, CD19, CD33 and MHC class II-positive cells with the respective mAbs. The CD4 + and CD8 + T cell subpopulations were further isolated from purified T cells by negative depletion with CD8 mAb VIT8 and CD4 mAb VIT4, respectively. In this study we used only a subpopulation with a purity of у95%.
Immunofluorescence analysis
For membrane staining, cells (5 × 10 5 ) were incubated for 30 min at 0-4°C with unconjugated mAbs. After washing twice with PBS, Oregon Green-conjugated goat anti-mouse antibody from Molecular Probes (Eugene, OR, USA) was used as second-step reagent. Binding of the chimeric mAb C2B8 was detected with an FITC-conjugated mAb (VIG-C2) which is specific for human IgG. Flow cytometric analysis was performed using a FACScan flow cytometer (Becton Dickinson Immunocytometry System, Palo Alto, CA, USA).
For suspension stainings of intracellular antigens we used the commercially available reagent combination Fix&Perm from An der Grub and followed the proposed procedure. Cells were first fixed for 15 min at room temperature (50 l cell suspension plus 100 l of formaldehyde-base fixation medium). After one washing with PBS, cells were resuspended in 100 l of permeabilization medium plus 20 l of fluorochrome-labeled mAb and treated for 15 min at room temperature.
Assessment of apoptosis
Daudi cells (2 × 10 6 ) were incubated with or without C2B8 (50 g/ml) or human IgG (50 g/ml) in 24-well plates (Corning-Costar Europe, Badhoevedorp, The Netherlands) for 8 and 24 h at 37°C. Hyperthermia treatment of Daudi cells was performed in parallel as positive control for the induction of apoptosis by culturing for 2 h at 43°C, followed by a resting period of 3 h at 37°C. 34 Afterwards, apoptosis was assessed by staining with FITC-labled annexin-V and PI and performing flow cytometric analysis. Postive staining with FITC-labeled annexin-V reflects a shift of phosphatidylserine from the inner to the outer layer of the cytoplasmic membrane, which occurs early in apoptosis. Annexin-V-positive and PI-negative cells were scored as apoptotic cells.
Cocultivation of DC with C2B8-treated Daudi cells
DC were generated as described by culturing purified blood monocytes for 7 days with a combination of GM-CSF (50 ng/ml) and IL-4 (1000 U/ml) in RPMI containing 10% FCS. 33, 35 For assessment of phagocytosis of C2B8-treated Daudi cells by DC, lymphoma cells were stained with the membrane dye dialcylcarboxycyanine (DIL; Molecular Probes) and mixed with DC at a ratio of 1:2. After cocultivation for 2 h at 37°C and at 0°C, DC were stained with FITC-labeled mAb W6/32 in order to distinguish MHC class I + DC from MHC class I − Daudi cells. Phagocytosis was then analyzed by flow cytometry and double positive cells were enumerated as DC loaded with lymphoma-derived cellular material. Internalization was approved in parallel by confocal microscopy. Cells were transfered on to glass bottom dishes (WillCo Wells, Amsterdam, The Netherlands) and analyzed by using an inverted Eclipse TE300 microscope equipped with a PCM 2000 confocal laser scanning system (Nikon Corporation, Tokyo, Japan). The influence of C2B8-treated Daudi cells on DC activation/maturation was investigated by mixing apoptotic lymphoma cells with DC at 1:5 ratio and coculturing them for 24 h at 37°C. Afterwards, the immunophenotype of DC was analyzed by flow cytometry and contaminating Daudi cell material was excluded due to their foreward/side scatter characteristics as well as by PI staining. For control, maturation of DC was induced in parallel by LPS stimulation (1 g/ml).
Activation of cytotoxic T cells
Purified peripheral blood T cells (1 × 10 5 /well) were cocultured with autologous DC (1 × 10 cells or DC pulsed with C2B8-treated Daudi cells in 200 l complete medium in 96-well U-bottom plates (CorningCostar). Six days later, the cytokines Il-2 (10 U/ml), IL-7 (1 ng/ml) and IL-12 (0.1 ng/ml) were added and after another culture period of 6 days the cells were harvested and induction of CTL activity was analyzed in a standard chromium release assay.
Cytotoxicity assay
Cytotoxicity was measured in a standard 4 h 51 Cr release assay. Briefly, 2 × 10 6 target cells were resuspended in 100 l PBS and labeled with 51 Cr (50 Ci) for 1 h at 37°C. After washing twice with medium, 5 × 10 3 target cells/well were added to triplicates of decreasing numbers of CTL in 96-well U-bottom plates. To determine the spontaneous release only medium was added to the target cells in three wells and to define the maximal release 100 l of a Trition X100 solution (2%) was added to a separate triplicate of wells with target cells. The cells were then centrifuged, except when mAb inhibition studies were performed, and incubated at 37°C for 4 h. Released 51 Cr was then harvested with a filter harvesting system (Skatron, Oslo, Norway) and measured on a ␥-counter Model 5000 from Packard, Topcount Instrument Co., Meriden, CT, USA). The percentage of specific lysis was calculated by the formula: (value of the probe − spontaneous release)/(maximal release − spontaneous release) × 100.
Results
Selection of a CD20
+ model system
In this study we wanted to learn whether treatment of tumor cells with an apoptosis inducing antibody eventually promotes the induction of a potentially protective CD8 + cytotoxic T cell (CTL) response against cell-associated antigens. For that purpose, we selected the chimeric CD20 mAb C2B8 and the lymphoma cell line Daudi as a model system.
As can be seen from Figure 1 , Daudi cells, a Burkitt lym- Leukemia phoma B cell, strongly express CD20 and react with the chimeric CD20 mAb C2B8 (Figure 1a) . Secondly, Daudi cells are ␤ 2 -microglobulin deficient and, thus do not express intact MHC class I molecules on their cell surface ( Figure 1a) . As a consequence, Daudi cells are unable to directly prime CD8 + T cell responses. However, free ␣-chains of HLA-A1 accumulate in the cytoplasm and can, when appropriately presented, induce specific anti-allo MHC class I responses (Figure 1b) .
Treatment of Daudi cells with the mAb C2B8 induces apoptosis
Engagement of CD20 molecules on B cell lines with mAb C2B8 has been shown before to induce growth inhibiting signals leading to apoptosis. 13 To re-evaluate whether Daudi cells are sensitive to mAb C2B8 and undergo apoptosis, we incubated them with mAb C2B8 or negative control IgG and analyzed them 8 and 24 h later. Results presented in Figure  2 demonstrate that the expression of phosphatidylserine molecules (PS) on the outer leaflet of the plasma membrane, an early sign of apoptosis as determined by annexin V-FITC binding, was already detectable on a large proportion of Daudi cells after 8 h of C2B8 treatment but not due to treatment with control IgG. Yet despite PS expression, a majority of C2B8-treated Daudi cells could still exclude propidium iodide (PI), a classical dye for DNA and marker for advanced cell death. Leukemia thermia treatment (Figure 2 ), known to be a strong trigger of programmed cell death. 40 
Dendritic cells phagocytose C2B8-treated Daudi cells
Several groups have recently demonstrated that DC phagocytose apoptotic and necrotic cells. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] We therefore wondered whether mAb C2B8-treated lymphoma cells would also be recognized and ingested by DC.
Results presented in Figure 3a demonstrate that C2B8-treated Daudi cells were readily phagocytosed after 2 h of coculture at 37°C but not at 0°C. In contrast, uptake of untreated Daudi cells or Daudi cells treated with control IgG was only marginal. Blocking of the Fc␥R on DC by pretreatment with human IgG only partially reduced the uptake of C2B8-treated Daudi cells by the DC. Thus, Fc␥R-mediated phagocytosis seems to be involved but does not play a major role.
Internalization was further confirmed in parallel by confocal microscopy ( Figure 3b ). The optical sections through a rep- resentative DC (green) clearly illustrate internalized Daudiderived cell debris (red).
Coculture of C2B8-treated lymphoma cells induces maturation of DC
Upon phagocytosis of apoptotic and/or necrotic cells by DC, peptides derived from cell debris-associated antigens were shown to be presented on MHC molecules of the DC. The decision whether such antigens become an immunogen or a tolerogen is made by the DC. 30 The maturation state of DC is critical in this respect and only mature DC are efficient stimulators of T cell responses. We therefore investigated the maturation stage of DC before and after cocultivation with mAb C2B8-treated, apoptotic Daudi cells.
Results presented in Figure 4 demonstrate that DC display characteristic signs of maturation upon inoculation with C2B8-treated Daudi cells. After 24 h of coculture the DC activation marker CD83 was found to be clearly expressed and co-stimulatory molecules such as CD40 or CD86 as well as MHC class II molecules were strongly upregulated similar to that observed upon LPS treatment, a classical DC maturation factor. 41, 42 By contrast, treatment of DC with mAb C2B8 alone showed no such effect.
DC pulsed with C2B8-treated lymphoma cells crossprime allo-reactive CTL
Since the uptake of mAb C2B8-treated Daudi cells was accompanied with an induction of DC maturation, we then evaluated whether such lymphoma cell-pulsed DC might cross-present antigens derived from Daudi and stimulate specific CTL activity in autologous T cells. To prove the specificity of such a CTL response, we selected two EBVtransformed lymphoblastoid B cell lines (LCL) with distinct HLA phenotypes as read out system. One of them, OM-LCL, is HLA-A1 + like Daudi cells, whereas LCL-5170 cells express an HLA-phenotype (HLA-A34 + ) unrelated to Daudi cells. Results presented in Figure 5 demonstrate that stimulation of T cells with autologous DC pulsed with mAb C2B8-treated Daudi cells elicited strong CTL activity. The CTL response was found to be specific for Daudi-derived allo-antigens (HLA-A1), since OM-LCL (HLA-A1 + ) but not HLA-A1
− LCL-5170 were recognized and lysed (Figure 5c ). Importantly, cross-presentation was a prerequisite for the induction of allogeneic CTL activity. mAb C2B8-treated Daudi cells in the absence of bystander DC as well as unloaded DC failed to activate CTL responses (Figure 5a, b) .
CD8 + T cells are responsible for lysis of MHC class Imatched target cells
We wondered whether induction of CTL activity was mediated via cross-presentation of Daudi-derived alloantigens
Leukemia
Figure 5
Induction of lymphoma-specific CTL activity by C2B8- via MHC class I or MHC class II molecules on DC. In order to elucidate this question, CD4
+ and CD8 + T cells were separated and stimulated by DC loaded with C2B8-treated lymphoma cells in parallel.
Results in Figure 6 clearly demonstrate that cytolytic activity was preferentially found within the CD8 + subpopulation. Purified CD8 + T cells stimulated by DC loaded with C2B8-treated Daudi cells gave 3-to 4-fold higher cytotoxic reponse compared to CD4
+ T cells activated in parallel under the same conditions. This observation is further supported by the finding that CTL responses could be inhibited with the blocking CD8 mAb VIT8 (data not shown). Thus, cross-priming of CD8 + T cells due to cross-presentation of Daudi-derived alloantigens via the MHC class I presentation pathway seems to be critically involved in the CTL response observed.
Leukemia
Figure 6
The cytotoxic activity is primarily mediated by CD8 + T cells. Purified CD4
+ and CD8 + T cell subpopulations of the same donor were stimulated with autologous DC pulsed with C2B8-treated Daudi cells and the cytotoxic activity of the individual subpopulations was tested against HLA-A1-matched OM-LCL cells (filled circles) and HLA-mismatched 5170 target cell (open squares). The figure shows the result of one out of two independently performed experiments.
Discussion
We have shown in this study in an in vitro model that induction of apoptosis in lymphoma cells upon engagement of CD20 with mAb C2B8 promotes uptake and crosspresentation of lymphoma cell-derived peptides on cocultured DC, which finally allows an efficient activation of allo-specific CTL. Our observations presented here suggest that treatment of tumor cells with antibodies, which are capable of inducing an apoptotic signal via their cell surface target structure, may not only contribute to their direct killing and elimination but may also induce potentially protective CTL responses against the tumor.
Humanizing of xenogenic monoclonal antibodies (mAbs) by genetic engineering has greatly improved their therapeutical utility and efficacy in humans in certain neoplastic malignancies. 5, 16 The chimeric CD20 mAb C2B8 (rituximab) is a prominent representative of this new generation of therapeutic mAbs and has been proposed as a treatment of choice for recurrent follicular non-Hodgkin's lymphomas. So far, the efficacy of mAb C2B8 is considered to be the result of concerted effector mechanisms which are directly elicited by the mAb. Since CD20 is stably expressed on the surface of B cells and not down-modulated upon binding of mAb C2B8 the mAb is able to recruit FcR-bearing effectors such as NK cells or macrophages. The strong correlation between therapeutic performance in vivo and antibody-dependent cellular cytotoxicity in vitro helped to establish the belief that cytotoxic cellular effectors as well as complement-dependent lysis provide the main arm of C2B8 activity. 1, [9] [10] [11] [12] In addition to these indirect cytotoxic effects, cross-linking of CD20 with C2B8 further induces growth inhibiting and apoptotic signals in lymphoma cell lines. [13] [14] [15] [16] [17] [18] [19] Our results presented in this study also clearly demonstrate that treatment of the Burkitt lymphoma cell Daudi with mAb C2B8 triggered pronounced apoptotic cell death within hours in the absence of immune effector cells or complement (Figure 2) . The combined action of these cell damaging mechanisms triggered by mAb C2B8 in vitro may explain the rapid depletion of normal and neoplastic B cells after C2B8 infusion found in B-NHL patients during the initial response.
Moreover, remission phases for several months up to years have been reported upon administration of C2B8 in responding patients. [4] [5] [6] [7] [8] Interestingly, this is not a unique property of C2B8 but has also been observed in lymphoma therapy with anti-idiotype antibodies. 45, 46 This raises the question whether certain mAbs work in two ways and induce a second cellular 'control mechanism' after the inital response which is no longer directly mediated by the mAb. So far, the underlying mechanism, via which dormancy of tumors in response to mAb application can be achieved, are incompletely understood. The results of a recent study reported by Nelson and co-workers suggest, however, that CTL might be critical in the control of disease progression of B cell lymphomas. 47 The results of this in vitro study imply that the accumulating debris of tumor cells caused by the mAb therapy might be the starting point for an additional, long-term effector mechanism initiated by DC and mediated by CTL. 48 However, it remains open whether this potentially important immunological reaction takes place in vivo. Therefore, we want to investigate in a future study whether lymphoma-specific, CTL-mediated immunity can be induced by C2B8 therapy in vivo in responding patients. The response rate reported for mAb C2B8 therapy in lymphoma patients is about 50%. The reason why C2B8 therapy fails in 50% of the patients is incompletely understood and may be simply due to a high tumor burden 43, 49 or due to different expression levels of CD55 and CD59, which are central regulators of complement-mediated cell lysis. 11 In view of this molecular heterogeneity of lymphoma cells it is intriguing to assume that not in all patients is an appropriate DC activating signal provided by mAb C2B8-treated, apoptotic lymphoma cells. In this case, cross-presentation of lymphoma cell-associated antigens would occur on immature DC and would be tolerogenic rather than stimulatory. Thereby, cross-presentation of lymphoma cell debris by DC has also to be regarded as a potential drawback which might be one of the reasons why C2B8 therapy is not successful. In this respect, the combination of mAbbased therapy with DC-activating stimuli such as CD40L or IFN-␣ should be considered in order to avoid potentially adverse effects on tumor-reactive T cells induced by crosspresentation.
